Commonly used methods of complementary medicine in the treatment of breast cancer

Breast Care

Volumn 8, Issue 5, 2013, Pages 341-347

  Hübner, Jutta ^a   Hanf, Volker ^b  

^a GOETHE UNIVERSITY   (Germany)

^b KLINIKUM FÜRTH   (Germany)

Author keywords

Alternative medicine; Breast cancer; Complementary medicine; Evidence based medicine; Supplements; Supportive therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CYTOCHROME P450 3A4; OMEGA 3 FATTY ACID; PHYTOESTROGEN; RETINOL; SELENIUM; TRACE ELEMENT; VITAMIN D; VITAMIN D RECEPTOR;

ACUPUNCTURE; ALTERNATIVE MEDICINE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHINESE HERB; CHINESE MEDICINE; DIET SUPPLEMENTATION; EDUCATIONAL STATUS; EUROPE; EXERCISE; FOOD ALLERGY; HOMEOPATHY; HORMONAL THERAPY; HUMAN; KETOGENIC DIET; LONG TERM CARE; LONG TERM SURVIVAL; LOW DRUG DOSE; LYMPHEDEMA; MOXIBUSTION; MULTIMODALITY CANCER THERAPY; MYALGIA; NONHUMAN; NUTRITIONAL DEFICIENCY; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SOCIAL STATUS; TEA; VISCUM ALBUM;

EID: 84890062300     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000355705     Document Type: Review

References (61)

1. Horneber M, Bueschel G, Dennert G, et al.: How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis. Integr Cancer Ther 2012;11:187-203.
2. Micke O, Bruns F, Glatzel M, et al.: Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 2009;1:22-30
3. Molassiotis A, Fernadez-Ortega P, Pud D, et al.: Use of complementary and alternative medicine in cancer patients: A European survey. Ann Oncol 2005;16:655-663.
4. Eschiti VS: Lesson from comparison of CAM use by women with female-specific cancers to others: it's time to focus on interaction risks with CAM therapies. Integr Cancer Ther 2007;6:313-344.
5. Eng J, Ramsum D, Verhoef M, et al.: A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2003;2:212-216.
6. Davidson R, Geoghegan L, McLaughlin L, et al.: Psychological characteristics of cancer patients who use complementary therapies. Psychooncology 2005;14:187-195.
7. Hann D, Baker F, Denniston M, Entrekin N: Longterm breast cancer survivors' use of complementary therapies: perceived impact on recovery and prevention of recurrence. Integr Cancer Ther 2005; 4:14-20.
8. Verhoef MJ, Trojan L, Armitage GD, et al.: Complementary therapies for cancer patients: Assessing information use and needs. Chronic Dis Can 2009; 29:80-88.
9. Hanf V: Complementary methods in breast cancer therapy. Breast Care (Basel) 2009;4:5-6.
10. Robinson A, McGrail MR: Disclosure of CAM use to medical practitioners: A review of qualitative and quantitative studies. Complement Ther Med 2004;12:90-98.
11. Yates JS, Mustian KM, Morrow GR, et al.: Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 2005;13:806-811.
12. Gröber U: Antioxidants and other micronutrients in complementary oncology. Breast Care (Basel) 2009;4:13-20.
13. Bairati I, Meyer F, Gélinas M, et al.: A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005;97:481-488.
14. Bairati I, Meyer F, Jobin E, et al.: Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients. Int J Cancer 2006;119:2221-2224.
15. Meyer F, Bairati I, Jobin E, et al.: Acute adverse effects of radiation therapy and local recurrence in relation to dietary and plasma beta carotene and alpha tocopherol in head and neck cancer patients. Nutr Cancer 2007;59:29-35.
16. Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized doubleblind comparison. N Engl J Med 1985;312:137-141.
17. Chen Q, Espey MG, Sun AY, et al.: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102:13604-13609.
18. Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008;19:115-124.
19. Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009;23:1679-1686.
20. Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:8031-8038.
21. Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2001;25:983-990.
22. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. Ascorbic acid in advanced malignancy. Ann Oncol 2008;19:1969-1974.
23. Yeom CH, Jung GC, Song KJ, et al.: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007;22:7-11.
24. Goodwin PJ, Ennis M, Pritchard KI, et al.: Prognostic effects of 25-hydroxy vitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757-3763.
25. McCullough ML, Bostick RM, Mayo TL: Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009;29:111-132.
26. Raimondi S, Johansson H, Maisonneuve P, et al.: Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009;30:1170-1180.
27. Khan QJ, Reddy PS, Kimler BF, et al.: Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010;119:111-118.
28. Crew KD, Shane E, Cremers S, et al.: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009;27:2151-2156.
29. Napoli N, Vattikuti S, Ma C, et al.: High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J 2010; 16:609-616.
30. Rastelli AL, Taylor ME, et al.: Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): A phase II, double-blind, placebocontrolled, randomized trial. Breast Cancer Res Treat 2011;129:107-116.
31. Singh S, Cuzick J, Mesher D, et al.: Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat 2012;132: 625-629.
32. Weisse K, Winkler S, Hirche F, et al.: Maternal and newborn vitamin D status and its impact on food allergy development in the German LiNA cohort study. Allergy 2013;68:220-228.
33. Beuth J: Evidence-based complementary medicine in breast cancer therapy. Breast Care (Basel) 2009; 4:8-12.
34. Bleys J, Navas-Acien A, Guallar E: Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 2008;168:404-410.
35. Dennert G, Zwahlen M, Brinkman M, et al.: Selenium for preventing cancer. Cochrane Database Syst Rev 2011;(5):CD005195.
36. Lee EH, Myung SK, Jeon YJ, et al.: Effects of selenium supplements on cancer prevention: metaanalysis of randomized controlled trials. Nutr Cancer 2011;63:1185-1195.
37. Klein EA, Thompson IM Jr, Tangen CM, et al.: Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-1556.
38. Lippman SM, Klein EA, Goodman PJ, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
39. Hatfield DL, Gladyshev VN: The outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv 2009;9:18-21.
40. Büntzel J, Riesenbeck D, Glatzel M, et al.: Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head neck cancer patients. Anticancer Res 2010;30:1829-1832.
41. Mücke R, Schomburg L, Glatzel M: Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010;70:825-835.
42. Micke O, Bruns F, Mücke R, et al.: Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 2003; 56:40-49.
43. Bruns F, Büntzel J, Mücke R, et al.: Selenium in the treatment of head and neck lymphedema. Med Princ Pract 2004;13:185-190.
44. Inoue M: Regular consumption of green tea and the risk of breast cancer recurrence: follow upstudy from the hospital-based Epidemiologic Research Program at Aiichi Cancer Center. Cancer Lett 2001;167:175-182.
45. Seely D, Tajima K, Mizutani M, et al.: The effect of green tea consumption on incidence of breast cancer and recurrence of breast cancer, a systematic review and meta-analysis. Integr Cancer Ther 2005;4:144-155.
46. Ogunleye AA, Xue F, Michels KB: Green tea consumption and breast cancer risk or recurrence: A meta-analysis. Breast Cancer Res Treat 2010;119: 477-484.
47. Stubert J, Gerber B: Isoflavones-mechanism of action and impact on breast cancer risk. Breast Care 2009;4:22-29.
48. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG: Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162-2168.
49. Horneber MA, Bueschel G, Huber R, et al.: Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008;(2):CD003297.
50. Kassab S, Cummings M, Berkovitz S, et al.: Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev 2009;(2):CD004845.
51. Milazzo S, Russell N, Ernst E: Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006;42:282-289.
52. Pommier P, Gomez F, Sunyach M, et al.: Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004;22:1442-1453.
53. Oberbaum M, Yaniv I, Ben-Gal Y, et al.: A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer 2001; 92:684-690.
54. Ezzo JM, Richardson MA, Vickers AB, et al.: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006;(2):CD002285.
55. Rada G, Capurro D, Pantoja T, et al.: Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;(9):CD004923.
56. Paley CA, Johnson MI, Tashani OA, et al.: Acupuncture for cancer pain in adults. Cochrane Database Syst Rev 2011;(1):CD007753.
57. Hanf V, Gonder U: Nutrition and primary prevention of breast cancer: foods, nutrients and breast cancer risk. Eur J Obstet Gynecol Reprod Biol 2005;123:139-149.
58. Hübner J, Marienfeld S, Abbenhardt C, Ulrich CM, Löser C: Wie sinnvoll sind 'Krebsdiäten'? Eine kritische Analyse als Grundlage für die ärztliche Beratung. Dtsch Med Wochenschr 2012;137: 2417-2422.
59. Otto C, Kämmerer U: Die ketogene Diät als Ernährungsoption für Tumorpatienten; krankheitsbedingte Mangelernährung. DGEM Schrift 2010, www.dgem.de.
60. Martinez-Outschoorn UE, Prisco M, Ertel A, et al.: Ketones and lactate increase cancer cell 'stemness', driving recurrence, metastasis and poor clinical outcome in breast cancer. Cell Cycle 2011;10:1271-1286.
61. Otto C, et al.: Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and mediumchain triglycerides. BMC Cancer 2008;8:122.